Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients

Area of Science:

• Immunology
• Neuroscience
• Biochemistry

Background:

• Interleukin-16 (IL-16) is implicated in multiple sclerosis (MS) pathogenesis, acting as a chemoattractant for immune cells involved in lesion development.
• Interferon-beta (IFN-β) is a common immunomodulatory therapy for MS.
• CD4(+) T-cell subsets, specifically Th1 and Th17 cells, are key autoimmune mediators affected by IFN-β treatment.

Purpose of the Study:

• To compare IL-16 serum levels in MS patients and healthy controls.
• To evaluate the long-term effect of IFN-β therapy on IL-16 serum levels in MS patients over two years.
• To analyze IL-16 expression in murine Th1 and Th17 cells, important autoimmune mediators.

Main Methods:

• IL-16 serum levels were measured using ELISA in 16 MS patients and 17 controls before and during 24 months of IFN-β1a therapy.
• Magnetic resonance imaging (MRI) was used to assess disease activity.
• IL-16 expression in in vitro differentiated murine myelin oligodendrocyte glycoprotein (MOG)-specific Th1 and Th17 cells was quantified via real-time PCR.

Main Results:

• MS patients exhibited significantly elevated IL-16 serum levels compared to controls, independent of MRI-determined disease activity.
• IFN-β1a therapy resulted in a significant, linear decrease in IL-16 serum levels starting from month 2.
• Murine myelin oligodendrocyte glycoprotein (MOG)-specific Th17 cells demonstrated higher IL-16 expression than Th1 cells.

Conclusions:

• The reduction of elevated IL-16 levels may contribute to the therapeutic efficacy of IFN-β1a in MS.
• Accessible IL-16 serum levels show potential as a biomarker for monitoring treatment response in MS patients.